Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Neuroendocrine Tumor (NET) Treatment Market

Neuroendocrine Tumor (NET) Treatment Market Size

  • Report ID: GMI10357
  • Published Date: Jul 2024
  • Report Format: PDF

Neuroendocrine Tumor Treatment Market Size

Neuroendocrine Tumor Treatment Market size reached a valuation of USD 2.5 billion in 2023, with a projected CAGR of 9.1% between 2024 and 2032, fueled by the rising global incidence of neuroendocrine tumors (NETs).

 

Technological advancements in diagnostics have notably improved the early and accurate detection of historically challenging NETs. This enhanced detection has, in turn, heightened the demand for effective treatment options. Moreover, heightened awareness of NETs among healthcare providers and the public has translated into more patients seeking treatment. The market has also seen a boost from the introduction and approval of novel therapies, particularly targeted treatments, broadening the treatment landscape for patients.
 

Pharmaceutical companies' increased R&D investments have played a pivotal role in the market's expansion. Furthermore, bolstered by supportive government policies and funding, collaborations between academic institutions and biopharmaceutical firms are fast-tracking innovations in oncology, propelling market growth.
 

Neuroendocrine tumor (NET) treatment encompasses a range of medical approaches tailored to manage these tumors, which originate from neuroendocrine cells exhibiting characteristics of both hormone-producing endocrine cells and nerve cells. Treatment decisions are influenced by factors such as tumor type, location, stage, grade, and the patient's overall health.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global neuroendocrine tumor (NET) treatment industry was valued at USD 2.5 billion in 2023 and is anticipated to register 9.1% CAGR between 2024 and 2032, fueled by the rising global incidence of NETs and the increasing technological advancements.

The hospitals & clinics segment is anticipated to reach USD 2.8 billion by 2032 due to their advanced infrastructure, comprehensive healthcare services, and access to cutting-edge diagnostic and therapeutic technologies.

North America neuroendocrine tumor treatment market is anticipated to reach USD 2.3 billion by 2032 due to the high prevalence of cancer and strong regulatory framework.

AVEO Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly & Company, F. Hoffmann-La Roche Ltd., Hutchison MediPharma Limited, Ipsen, and Jubilant Life Sciences Ltd., among others.

Neuroendocrine Tumor Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 267
  • Countries covered: 22
  • Pages: 155
 Download Free Sample